SCHEMBL3019411

SCHEMBL3019411

COc1ccc(N2CCN(c3nccc(Nc4ccc(N5CCOCC5)cc4C)n3)CC2(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
PSEN1 P49768 4/20 0.52
PSEN2 P49810 4/20 0.52
APH1B Q8WW43 4/20 0.52
NCSTN Q92542 4/20 0.52
APH1A Q96BI3 4/20 0.52
PSENEN Q9NZ42 4/20 0.52
MAPK1 P28482 2/20 0.43
TAAR1 Q96RJ0 1/20 0.43
KDR P35968 2/20 0.42
BRAF P15056 1/20 0.42
PIK3CA P42336 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
MAPT P10636 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.42
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3029840 0.94 PSEN1 (0.54) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3028351 0.87 PSEN1 (0.53) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3028364 0.86 PSEN1 (0.50) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3011624 0.86 PSEN1 (0.63) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3025804 0.85 PSEN1 (0.51) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3018904 0.84 PSEN1 (0.61) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3017611 0.83 PSEN1 (0.49) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3027751 0.82 PSEN1 (0.53) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3030548 0.81 PSEN1 (0.53) CYP3A4CYP2D6CYP2C9PSEN1PSEN2
SCHEMBL3023188 0.81 PSEN1 (0.77) CYP3A4CYP2D6CYP2C9PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
WO-2008099210-A2 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS MERCK & CO., INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204230-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS PSEN1, PSEN2, APP CYP3A4 2378/4885CYP2D6 3553/4885CYP2C9 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.